City of Hope Awarded $23.7 Million to Map Biomarkers Linked to Treatment Resistance in Patients With Common Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report, has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The grant will help City of Hope create a bio map of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer (NSCLC).
'Changes in cancer may occur over time, creating resistance to immunotherapy and complicating oncologists' ability to identify the next best treatment approach,' said City of Hope's Ravi Salgia, M.D., Ph.D.
City of Hope's Beckman Research Institute researchers will also test new biomarker-guided therapies in near real time NSCLC, which accounts for 87% of all lung cancer cases. By shaping physicians' management of the disease, the new findings offer promise for improving treatment success and extending the lives of the 200,000 patients diagnosed each year in the United States.
A six-year clinical trial, enrolling 535 patients, will provide the cornerstone for the City of Hope project, which is part of ARPA-H's Advanced Analysis for Precision Cancer Therapy (ADAPT) program. The up to $142 million initiative combines the latest technologies with the nation's top expertise in tumor biology to deliver customized cancer care that adapts to a patient's disease as it evolves.
'Changes in cancer may occur over time, creating resistance to immunotherapy and complicating oncologists' ability to identify the next best treatment approach,' said Ravi Salgia, M.D., Ph.D., professor and chair of City of Hope's Department of Medical Oncology & Therapeutics Research, the Arthur & Rosalie Kaplan Chair in Medical Oncology, principal investigator with City of Hope's Aritro Nath, Ph.D., and Jyoti Malhotra, M.D., M.P.H. 'Developing a biomap that detects mutations and other alterations early and predicts a patient's cancer trajectory will enable us to match treatments to evolving tumor biology and improve our patients' long-term survival.'
Until now, cancer studies have focused on first-line therapy and lacked the flexibility to modify treatments as tumors grow. City of Hope will design its clinical trial to adjust treatment as resistance arises, with the goal of increasing progression-free survival by 50% in at least one patient group.
'Doctors have historically treated advanced non-small cell lung cancer with immune checkpoint inhibitors, sometimes combined with chemotherapy,' explained Dr. Nath, City of Hope assistant professor with the Division of Molecular Pharmacology, Department of Medical Oncology & Therapeutics Research. 'The main biomarker used to select immunotherapy, however, is not very reliable, with a patient response rate of less than 40%. We don't know why some patients become resistant to checkpoint inhibitors, and we have no good biomarkers to guide the choice of secondary treatments.'
City of Hope intends to change that through meticulous monitoring and measurement of tumor changes in near real time.
Dr. Salgia and his colleagues will collect samples and detailed data at regular intervals from patients throughout the course of treatment. The researchers will monitor tumor trajectory and patients' response to treatment using state-of-the-art diagnostic techniques like liquid biopsies, single cell sequencing and radio imaging, relying on rapid turnaround times for comprehensive tumor measurements.
Instead of measuring a few data types at a single timepoint with limited predictive ability, the ADAPT program will take many measurements of diverse data over time and through multiple lines of treatments. The insights gleaned will help identify newly acquired resistant traits in tumors, predict the right therapies at each point in a patient's treatment and identify strategies that provide better long-term prognoses.
'We expect our collaboration with ADAPT will uncover predictive biomarkers that will enhance patient treatment and boost immunotherapy responses in non-small cell lung cancer,' said Dr. Malhotra, associate professor with the Department of Medical Oncology & Therapeutics Research and interim division chief of Thoracic Medical Oncology, City of Hope, Los Angeles. 'The information we gather will allow for informed adjustments in treatments and improve patient outcomes.'
Equally important, the trial will leverage City of Hope's network of more than 35 clinical sites whose populations reflect the nation's lung cancer patients. The research team anticipates enrolling its first patients within 12 months.
With over 30 years of experience spearheading clinical trials and translational research, Dr. Salgia's leadership has been instrumental in uncovering key variants in lung cancer. He oversees more than 130 medical oncologists, including a nationwide team of 30 clinicians dedicated to lung cancer.
City of Hope investigators will fund the development, testing and matching of new biomarkers with therapeutic options that are now available or in a clinical trial. Algorithms and aggregate datasets developed under the program will be made publicly available, allowing scientists around the world to visualize trends and evaluate their implications and insights in near real time.
'We are incredibly excited to launch this ambitious project,' said Dr. Salgia. 'Our analysis of host and tumor biology will help clinicians counter the limits of current treatment choices and lead to better patient management strategies for advanced and metastatic non-small cell lung cancer.'
About City of Hope
City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report at its core, City of Hope's uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
City of Hope Leads AI-Powered Health Care Innovations and Launches Generative AI Tool to Save Lives and Enable Nationwide Best-in-Class Cancer Care
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report, is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research. City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research. Share 'With the rise of AI, health care systems like City of Hope are seizing the opportunity to transform physician workloads and fuel more focused, personalized patient care,' said Simon Nazarian, City of Hope chief digital and technology officer and system executive vice president. Among City of Hope's most exciting health care innovations is a novel generative AI platform that leverages multiple commercial and open-source AI models. HopeLLM — powered by City of Hope's proprietary technology and data — removes the administrative burden of new patient onboarding, matches patients to clinical trials, enables generative AI responses personalized to individual patient records and extracts real-world data for research. 'By summarizing massive information in seconds, HopeLLM removes a barrier between the patient and the doctor. Instead of spending time finding information in the history of previous tests and treatments, doctors can spend time and effort in getting patients and caregivers to understand treatment options. Instead of the frustration of trying to find information, doctors are able to create more joy as they deliver patient care,' said Vijay Trisal, M.D., City of Hope system chief clinical officer and the Dr. Norman & Melinda Payson Professor in Medicine. HopeLLM, is a revolutionary time saver that may be used by clinicians across City of Hope's national clinical network, enabling patients to receive world-class cancer care regardless of which City of Hope location they visit. In 2024 alone, City of Hope onboarded more than 150,000 patients. Doctors often see new patients with extensive medical histories spanning 10 to 20 years of test results, notes and treatment reports. Doctors need to spend significant time — often during nonworking hours — to review hundreds of pages, leading to less time interacting directly with patients. Additionally, HopeLLM instantly points out a patient's clinical trial eligibility and automatically extracts key data points into research-ready formats, converting hours of manual chart review into seconds of AI-driven insight. 'We're not just building point solutions; we have built the engine for a learning health system where every patient interaction accelerates the next breakthrough,' says Nasim Eftekhari, M.S., City of Hope chief AI and analytics officer and system vice president. Since 2017, City of Hope has been developing, deploying and optimizing life-saving AI-driven predictive models that are actively integrated into clinical workflows. These AI models help identify critical risks — such as sepsis in vulnerable populations and complications in surgical procedures — enabling timely clinical interventions that enhance patient outcomes and improve patient quality of life. Importantly, these predictive models provide risk scores along with contextual explanations that clarify the factors driving the prediction, empowering responsible AI-driven clinical decision-making support. City of Hope's pioneering AI initiatives extend to oncology drug discovery, early cancer detection and prevention, advanced diagnostics and deeper insights into cancer evolution and disease progression. As an organization that both develops and uses AI tools, City of Hope is committed to harnessing artificial intelligence to enhance patient care, advance research and improve health care efficiency. HopeLLM exemplifies City of Hope's AI work, where people with cancer benefit directly. For example, patients and doctors typically share the burden of providing and verifying medical history. However, HopeLLM shifts this responsibility away from patients, helping them to receive more personalized care and engage in focused, future-looking discussions with their doctors. HopeLLM allows patients to concentrate on their primary responsibility: recovery. To receive a second opinion at City of Hope Los Angeles, call 888-720-1621 or visit this webpage. About City of Hope City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report at its core, City of Hope's uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Medscape
a day ago
- Medscape
PROs Enhance Oncology Care Despite No OS Gain
This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman, from City of Hope. I'd like to briefly discuss a very important paper that recently appeared in Nature Medicine , entitled, 'Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.' I think those in the oncology community who are participating in clinical research are increasingly aware of how important, based upon trial design, patient-reported outcomes (PROs) are. Increasingly, this strategy is being considered for standard of care in academic medical centers, community oncology centers, and individual practices. Much of this enthusiasm comes out of the results of trials that have been reported in high-impact journals, which have suggested that, [in regards to] PROs, if you do this, you might actually improve survival in addition to improving quality of life. Very importantly, the studies that have been conducted to date have really focused more on the academic medical centers, the cancer centers, and unique patient populations. This study was an incredibly important follow-up trial from these earlier studies and really looked more at the population basis for the potential value of PROs. Again, this was a trial, but of course, we're looking at what the value may be outside of the clinical setting. This was a large, cluster-randomized trial looking at 52 oncology practices that were randomized to either do these surveys of symptom management or usual care without the survey. The PRO practice patients were invited to complete weekly symptom surveys. For severe or worsening symptoms, importantly, alerts were sent to the care team. Patients completed these weekly. If there was something that was severe or worsening, information went to the care team. Obviously, the individual practices that were not randomized to the PRO surveys did whatever program they might have had already. The primary outcome was an improvement in overall survival (OS), again, based upon previous studies. Secondary outcomes included emergency room visits, time to deterioration of physical function, health-related quality of life, and quite frankly, satisfaction with this tool — were they interested in it and did it seem beneficial. Here are the results. In all, 1191 patients were enrolled. In my opinion, not surprisingly, there was no difference in OS. Let me say, it would be very difficult to see in a study like this, with multiple different patient populations and a well-designed trial, that you could actually tease out an improvement in OS in a large patient population with all the other factors involved. For OS, surely there might be patients who are undergoing intensive chemotherapy or patients getting bone marrow transplantation where you might be able to really find a major impact on survival. In this large patient population, which is what we're focusing on here, a statistical improvement in OS would be difficult, but not the only important endpoint. Here are the rest of the results. The time to first emergency room visit was significantly prolonged in the patients who participated in the PRO survey. There was a 6% decrease overall in the emergency room visits — think of the time and effort for patients and cost that was eliminated. There were fewer overall visits at 12 months. The use of the symptom survey significantly delayed the deterioration in physical function symptoms and improved health-related quality of life. These are critically important issues, every one of them, for the practice of oncology and our goals. In addition, 77% of patients felt that the PRO survey tool improved their discussions with their care team and made them feel more in control of their own care. As evidence of the value here, 91.5% of the patients completed — on a weekly basis — these survey estimates. If they weren't interested and they didn't think it of value, surely that number would've been much lower. Again, this is a very important study. The investigators said they're planning on doing additional studies not focusing on OS as the primary endpoint, which I certainly agree with. The results are very important, and clearly, this is the type of strategy that we need to consider cost-effective ways for implementation in our routine care. Thank you for your attention.
Business Upturn
a day ago
- Business Upturn
Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment
By Aditya Bhagchandani Published on June 24, 2025, 09:50 IST Glenmark Pharmaceuticals has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its entry into the immuno-oncology space. This anti-PD-1 monoclonal antibody, developed by global oncology firm BeiGene (now BeOne Medicines), is approved for the treatment of advanced non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC). The drug is designed to restore T-cell function and minimize off-target immune suppression, having shown strong efficacy and safety in global trials. Already approved in over 46 countries including the U.S. and EU, TEVIMBRA has been used in treating more than 1.5 million patients worldwide. Glenmark's President Alok Malik stated that the company is committed to transforming cancer care in India by making cutting-edge immunotherapies accessible. The launch comes at a time when cancer incidence in India is sharply rising, especially NSCLC and ESCC which dominate their respective cancer types in the country. This milestone aligns with Glenmark's broader ambition to build a globally benchmarked oncology portfolio, adding to its existing focus areas of respiratory and dermatology. Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
